1. Home
  2. PMT vs GERN Comparison

PMT vs GERN Comparison

Compare PMT & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PennyMac Mortgage Investment Trust of Beneficial Interest

PMT

PennyMac Mortgage Investment Trust of Beneficial Interest

HOLD

Current Price

$10.53

Market Cap

915.6M

Sector

Real Estate

ML Signal

HOLD

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.27

Market Cap

821.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PMT
GERN
Founded
2009
1990
Country
United States
United States
Employees
7
258
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
915.6M
821.1M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
PMT
GERN
Price
$10.53
$1.27
Analyst Decision
Hold
Hold
Analyst Count
5
3
Target Price
$13.50
$2.17
AVG Volume (30 Days)
975.2K
14.2M
Earning Date
05-05-2026
05-06-2026
Dividend Yield
13.33%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$26.91
Revenue Next Year
$1.55
$43.75
P/E Ratio
$12.59
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.23
$1.04
52 Week High
$13.80
$2.01

Technical Indicators

Market Signals
Indicator
PMT
GERN
Relative Strength Index (RSI) 35.38 32.94
Support Level N/A $1.24
Resistance Level $12.82 $1.29
Average True Range (ATR) 0.28 0.09
MACD -0.05 -0.02
Stochastic Oscillator 16.04 10.42

Price Performance

Historical Comparison
PMT
GERN

About PMT PennyMac Mortgage Investment Trust of Beneficial Interest

PennyMac Mortgage Investment Trust is a specialty finance company that invests mainly in residential mortgage loans and mortgage-related assets. The company's operations include activities such as the production and servicing of financial securities based on residential loans and the pooling and reselling of high-credit-quality mortgages. The company operates through three segments: correspondent production, credit-sensitive strategies, interest-rate-sensitive strategies. The Credit sensitive strategies segment generates income via investments in CRT arrangements, subordinate MBS, distressed loans, and real estate.

About GERN Geron Corporation

Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.

Share on Social Networks: